A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
A phase 1/2 trial of TCC1727 tablet（1） in advanced solid tumours, run by Beijing Tide Pharmaceutical Co., Ltd, now recruiting.
Overview
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. is a phase 1/2 interventional study registered as NCT05970016 by Beijing Tide Pharmaceutical Co., Ltd, with 56 participants planned, started 2023-08-07 and due to reach its primary completion in 2025-07-30. Interventions recorded: TCC1727 tablet（1） and TCC1727 tablet（2）.
Similar pages
not linked directly; found by shared links- TrialAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Shares Beijing Tide Pharmaceutical and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAuger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.